NewLink Genetics Corporation (NLNK): Product News News

NLNK – Reports initial data from Phase 1 NLG2105 study evaluating indoximod in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors.


Key Facts Surrounding This News Item


  • NLNK had a POWR Rating of F (Strong Sell) coming into today.
  • NLNK was -17.15% below its 10-Day Moving Average coming into today.
  • NLNK was -29.24% below its 20-Day Moving Average coming into today.
  • NLNK was -36.70% below its 50-Day Moving Average coming into today.
  • NLNK was -42.61% below its 100-Day Moving Average coming into today.
  • NLNK was -46.53% below its 200-Day Moving Average coming into today.
  • NLNK had returned -44.88% year-to-date leading up to today’s news, versus a -0.24% return from the benchmark S&P 500 during the same period.

More Info About NewLink Genetics Corporation (NLNK)


NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve the lives of patients with cancer. The company was founded in 1999 and is based in Ames, Iowa. View our full NLNK ticker page with ratings, news, and more.

NLNK at a Glance

NLNK Current POWR Rating™
Overall POWR Rating™
NLNK Current Price $1.73 3.35%
More NLNK Ratings, Data, and News

NLNK Price Reaction

The day of this event (Apr. 16, 2018)
NLNK Closing Price$4.13 7.72%
NLNK Volume2,162,800
53.86% from avg
Leading up to this event
NLNK 1-mo return38.26%
After this event
NLNK 1-day return2.19%
NLNK 3-day return0.89%
NLNK 5-day return1.54%

NLNK Price Chart


The Top Stocks For 2019

More NewLink Genetics Corporation (NLNK) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NLNK News
Page generated in 0.8296 seconds.